Global /Norway /Healthcare /Medical Devices /AZT
chevron_leftBack
ArcticZymes Technologies ASA logo

ArcticZymes Technologies ASA

AZT
OSL: AZT Delayed
21.30NOK 2.4%
2.25 USD
As of 6 June 2026, ArcticZymes Technologies ASA has a market cap of $113.67M USD, ranking #24659 globally and #149 in Norway. It ranks #2206 in the Healthcare sector, and #454 in the Medical Devices industry.
Global Rank
24659
Country Rank
149
Sector Rank
2206
Industry Rank
454
Key Stats
Market Cap
$113.67MUSD
1.06B NOK
Enterprise Value
$84.83MUSD
802.91M NOK
Revenue (TTM)
$12.65MUSD
118.21M NOK
EBITDA (TTM)
$808.97KUSD
7.66M NOK
Net Income (TTM)
$1.06MUSD
9.88M NOK
EBITDA Margin
6.5%
Profit Margin
8.4%
PE Ratio
109.5
Forward PE
52.1
PS Ratio
9.0
PB Ratio
3.1
EV/EBITDA
67.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Michael Akoh open_in_new
Employees
53
Founded
1990
Website
arcticzymes.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2.4% 4% 9.5% -11% -31% 24%

News

Loading...

Markets

Exchange Ticker Price
Euronext Oslo Børs
MIC: XOSL
PRIMARY
AZT
ISIN: NO0010014632
Shares Out.:
51.071M1 Shares Float: 40.812M2
TV:
SA:
YF:
GF:
BA:
AZT
MS:
21.30 NOK
London Stock Exchange
MIC: XLON
0DRV
ISIN: NO0010014632
TV:
SA:
YF:
GF:
BA:
MS:
19.93 NOK
Nasdaq Stockholm
MIC: XSTO
BIOTECO (AZTO)
ISIN: NO0010014632
TV:
SA:
YF:
GF:
BA:
MS:
22.40 NOK
Show all 4 markets
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Similar Companies

Industry: Medical Devices (Norway)
Name
Market Cap diff.
PE
MEDI
$450.22M
4.21B NOK
296%
26.4
PHO
$191.61M
1.79B NOK
69%
-
$71.96M
672.45M NOK
-37%
50.6
$40.83M
381.57M NOK
-64%
-
LIFE
$12.76M
119.25M NOK
-89%
-
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
152K%
25.8
$160.73B
141K%
56.7
$159.07B
140K%
25.6
DHR
$126.55B
111K%
34.7
SYK
$120.69B
106K%
38.3
MDT
$101.9B
90K%
22.2
chevron_leftBack